Bone Regeneration
Regenerating the patient's own bone
OssiGel stimulates full bone regeneration at the defect site, using the patient's own biology instead of a donor graft or a synthetic growth factor.
The efficacy data
In a critical-sized femoral defect in an immunocompetent rat model, OssiGel achieved full bridging in 13 of 13 animals by 12 weeks, with bone volume in the defect reaching 87 mm³. Untreated controls showed no robust repair. Only a high dose of rhBMP-2 and a syngeneic living cartilage graft matched that bridging performance, and both carry downsides OssiGel avoids, BMP-2's dose-dependent side effects and the donor-matching complexity of a living graft. Mechanically, OssiGel-regenerated femurs reached stiffness statistically equivalent to native bone. The result held across mouse, rat and sheep models.
See the full OssiGel material profile
vs. rhBMP-2 (e.g. Infuse®)
Matches the bone-bridging performance of only the highest tested rhBMP-2 dose in a critical-sized rat femoral defect study, without the supraphysiologic dosing that drives BMP-2's known side effects, uncontrolled ectopic bone formation, inflammation, osteolysis and radiculitis.
vs. autograft
Off-the-shelf and immediately available. No second surgical site, avoiding the donor-site morbidity associated with autograft harvest, roughly 19% donor-site complication rate and 35 to 40 extra minutes of OR time.
vs. allograft
Actively instructs new bone formation through endochondral ossification, an osteoinductive mechanism that goes beyond allograft's role as a passive scaffold.
This application is built for clinicians, dentists, medical companies and investors evaluating a near-term therapeutic path.